ADCT - ADC Therapeutics SA
NYSE
->
Healthcare
->
Biotechnology
Epalinges,
Switzerland
Type: Equity
ADCT price evolution
ADCT
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $25.18 | $21.18 | $23.87 | $24.04 |
| Inventory | $16.18 | $22.73 | $19.43 | $18.25 |
| Total current assets | $336.29 | $375.6 | $412.81 | $380.01 |
| Long term investments | ||||
| Property, plant & equipment | $16.13 | $15.53 | $16.37 | $15.71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $354.78 | $466.9 | $507.3 | $467.67 |
| Current liabilities | ||||
| Accounts payable | $15.57 | $8.98 | $11.69 | $8.69 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $67.67 | $78.21 | $80.58 | $81.09 |
| Long term debt | $426.48 | $413.05 | $407.4 | $324.52 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $503.03 | $521.08 | $515.89 | $429.99 |
| Shareholders' equity | ||||
| Retained earnings | -$1068.7 | -$1023.05 | -$976.61 | |
| Other shareholder equity | -$148.25 | -$0.34 | -$0.05 | -$0.21 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $466.54 | $439.19 | ||
| Short term investments | ||||
| Net receivables | $25.18 | $74.35 | $31.04 | $1.7 |
| Inventory | $16.18 | $18.56 | $11.12 | |
| Total current assets | $336.29 | $446.01 | $525.18 | $450.45 |
| Long term investments | $41.24 | $47.91 | ||
| Property, plant & equipment | $16.13 | $9.98 | $11.23 | $4.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $63.24 | |||
| Total investments | ||||
| Total assets | $354.78 | $529.17 | $617.97 | $513.69 |
| Current liabilities | ||||
| Accounts payable | $15.57 | $12.35 | $12.08 | $5.28 |
| Deferred revenue | ||||
| Short long term debt | $13.39 | $3.63 | ||
| Total current liabilities | $67.67 | $98.96 | $73.94 | $40.44 |
| Long term debt | $426.48 | $316.16 | $305.82 | $34.77 |
| Total noncurrent liabilities | $137.75 | |||
| Total debt | ||||
| Total liabilities | $503.03 | $440.44 | $451.88 | $178.19 |
| Shareholders' equity | ||||
| Retained earnings | -$925 | -$924.88 | -$694.86 | |
| Other shareholder equity | -$148.25 | -$0.36 | $102.83 | $43 |
| Total shareholder equity | $166.09 | $335.5 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $16.79 | $14.49 | $19.28 | $18.99 |
| Cost of revenue | ||||
| Gross Profit | $15.57 | $14.13 | $18.69 | $18.4 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $55.55 | $51.53 | $57.75 | $69.38 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $43.17 | -$0.09 | -$6.61 | -$0.26 |
| Interest expense | -$9.62 | -$9.8 | -$14.21 | -$8.91 |
| Net income | ||||
| Net income | -$85.03 | -$47.81 | -$47.12 | -$59.43 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $69.56 | $209.91 | ||
| Cost of revenue | $141.82 | |||
| Gross Profit | $67.03 | $207.83 | -$141.82 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $77.23 | |||
| Total operating expenses | $233.01 | $328.73 | $219.05 | |
| Operating income | -$219.05 | |||
| Income from continuing operations | ||||
| EBIT | -$219.05 | |||
| Income tax expense | $39.11 | $1.14 | $0.33 | |
| Interest expense | -$35.78 | $8.01 | -$4.93 | |
| Net income | ||||
| Net income | -$240.05 | -$155.8 | -$246.29 | |
| Income (for common shares) | -$246.29 | |||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3.22 | -$2.69 | -$2.03 | -$1.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $73.88 | $72.24 | $74.54 | -$0.2 |
| Effect of exchange rate | $0.18 | $0.03 | $0.15 | $0.09 |
| Change in cash and equivalents | -$47.84 | -$16.03 | $21.07 | -$15.89 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$230.03 | -$246.29 | ||
| Operating activities | ||||
| Depreciation | $2.55 | $1.93 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$233.38 | -$168.73 | ||
| Investing activities | ||||
| Capital expenditures | -$3.43 | -$0.8 | ||
| Investments | ||||
| Total cash flows from investing | -$3.22 | -$2.51 | -$6.67 | -$2.83 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $48.61 | $61.75 | ||
| Total cash flows from financing | $73.88 | -$0.59 | $267.39 | $494.97 |
| Effect of exchange rate | $0.18 | -$0.21 | $0.01 | $0.23 |
| Change in cash and equivalents | -$47.84 | -$140.1 | $27.35 | $323.64 |
News
Fundamentals
| Market cap | $386.24M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 82.53M |
| Revenue | $69.56M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$239.38M |
| Revenue Q/Q | -75.94% |
| Revenue Y/Y | N/A |
| P/E ratio | -1.61 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 5.55 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.90 |
|---|---|
| ROA | -53.29% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.97 |
| Quick ratio | 4.73 |